SURGERY EARLY AFTER DES IMPLANTATION

Slides:



Advertisements
Similar presentations
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY Working Group:
Advertisements

When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.
After cardiac arrest: emergency coronary angiography for all? Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy
Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy Educational Fellowship in PCI.
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Pros and cons of FFR in multivessel disease: from FAME to ACS Giuseppe Biondi Zoccai University of Modena and Reggio Emilia, Modena, Italy
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
New generation devices for the femoro-popliteal district Giuseppe Biondi Zoccai University of Modena and Reggio Emilia
CURRENT PUBLICATION TRENDS IN INTERVENTIONAL CARDIOLOGY Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Biondi-Zoccai: Peripheral interventions – metcardio.org Basic principles of peripheral interventions Giuseppe Biondi Zoccai University.
ACUTE CORONARY SYNDROMES:
8 February 2012, 12:30-13:10 A journey into bioclinical evidence: from bench... to bedside... to population Giuseppe Biondi Zoccai
A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.
Setting up a hybrid suite: truth or myth? Giuseppe Biondi Zoccai, MD University of Modena and Reggio Emilia
Tips and tricks for performing standard meta-regression analysis with SPSS Giuseppe Biondi Zoccai Division of Cardiology, Department of Internal Medicine,
Applications of bivalirudin in interventional cardiology
Title1 Brain Natriuretic Peptide Levels Have A Significant Prognostic Role In Patients With Suspected Or Confirmed Acute Pulmonary Embolism: Evidence From.
PCI vs. CABG: Review of the evidence and suggestions Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Giuseppe Biondi Zoccai Division of Cardiology University of Turin, Turin Critical aspects of trials on the new generation DES 31st.
Is personalized medicine a hoax? Giuseppe Biondi Zoccai, MD University of Modena and Reggio Emilia
Biondi-Zoccai: CT & coronary angiography – metcardio.org Why coronary CT is inferior to invasive coronary angiography Giuseppe.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino
Multivessel PCI on top of culprit lesion revascularization? No way!
COMPLETE REVASCULARIZATION IN ELDERLY - When it’s contraindicated
Gender-related differences in carotid plaque features: focus on instability and inflammation Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.
PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.
Thrombectomy: beneficial (if ever) only in highly selected patients Prof. Imad Sheiban University of Turin, Turin, Italy.
Primer on statistical reporting and analyses for continuous variables Giuseppe Biondi Zoccai University of Turin, Turin, Italy
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Follow-up Clinico e Trattamento Post- Rivascolarizzazione Percutanea Giuseppe Biondi Zoccai University of Turin, Turin, Italy Marrakesh,
Drug-eluting stent meta-analyses & Long-term follow-up of high-risk subsets: Reconciling the evidence DES e BMS: riflessioni e pensieri 23 febbraio 2007,
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Drug-Eluting Stents in Challenging Lesions: Randomized Trials and Registries.
Prasugrel in all ACS Patients! Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy
How To Minimize Bleeding In The Cath Lab
Giuseppe Biondi Zoccai, M.D.
Primer on Adjusted Indirect Comparison Meta-Analyses
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
Optima DES system: The stent has multiple grooves (reservoirs) on its abluminal surface into which the drug is loaded. Optima DES system: The stent has.
Glenn N. Levine et al. JACC 2016;68:
Achieving Long-Term Protection Post-MI
Gilles Montalescot, ACTION Study Group, Paris
Giuseppe Biondi Zoccai
A primer on repeat (paired) measure analysis in SPSS
Glenn N. Levine et al. JACC 2016;68:
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Giuseppe Biondi Zoccai
Terms of Use. Terms of Use.
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Giuseppe Biondi Zoccai University of Turin, Turin, Italy
Giuseppe Biondi Zoccai, MD
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
P. Omedé,1 A. Abbate,4 G. P. Trevi,1 and I. Sheiban1
Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
PREDICTORS OF ADVERSE EVENTS IN PATIENTS WITH UNPROTECTED LEFT MAIN DISEASE TREATED WITH DRUG-ELUTING STENTS: EVIDENCE FROM A COLLABORATIVE META-REGRESSION.
John A. Bittl et al. JACC 2016;68:
BENEFITS OF CLOPIDOGREL IN PATIENTS UNDERGOING CORONARY STENTING SIGNIFICANTLY DEPEND ON LOADING DOSE: EVIDENCE FROM A SYSTEMATIC REVIEW AND META-REGRESSION.
Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.
ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.
Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.
Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.
Presentation transcript:

SURGERY EARLY AFTER DES IMPLANTATION THERAPEUTIC IMPLICATIONS It depends on which surgery Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, gbiondizoccai@gmail.com 20/10/2010 - 16.05-16.15

Timing from DAT withdrawal and ST Artang et al, AJC 2007

Temporal risk from PCI to surgery Cruden et al, Circ Cardiovasc Interv 2010

Predictors of stent thrombosis Grines et al, Circ 2007

Ischemic risk of surgery Fleisher et al, Circ 2007

Bleeding risk of surgery O’Riordan et al, Arch Surg 2009

ESC Guidelines Wijns et al, EHJ 2010

Balancing bleeding & ischemic risk Heart, Lung and Circulation 2010

Management of patients needing surgery Di Minno et al, Intern Emerg Med 2009

Bridging therapy Savonitto et al, BJA 2010

Bridging therapy Savonitto et al, BJA 2010

What to do if bleeding occurs? O’Riordan et al, Arch Surg 2009

Continue DAT in all but few cases Take home messages Individualize treatment depending on bleeding risk, ischemic risk and surgeon’s skills Continue DAT in all but few cases If DAT cannot be enforced, use bridging therapy plus aspirin

Thank you for your attention For any correspondence: gbiondizoccai@gmail.com For these and further slides on these topics feel free to visit the metcardio.org website: http://www.metcardio.org/slides.html